In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China

Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02008-16. doi: 10.1128/AAC.02008-16. Print 2017 Feb.

Abstract

Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.

Keywords: Mycoplasma pneumoniae; lefamulin; pleuromutilin; pneumonia; susceptibility testing.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Azithromycin / pharmacology
  • China
  • Diterpenes / pharmacology
  • Doxycycline / pharmacology
  • Drug Resistance, Bacterial
  • Erythromycin / pharmacology
  • Europe
  • Fluoroquinolones / pharmacology
  • Macrolides / pharmacology*
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Mycoplasma pneumoniae / drug effects*
  • Polycyclic Compounds
  • United States

Substances

  • Anti-Bacterial Agents
  • Diterpenes
  • Fluoroquinolones
  • Macrolides
  • Polycyclic Compounds
  • pleuromutilin
  • Erythromycin
  • Azithromycin
  • Doxycycline
  • Moxifloxacin